Boston Scientific Corp. reported positive data for two key atrial fibrillation therapies at AF Symposium 2025 on January 17.
Boston Scientific (NYSE: BSX) today reported data from separate studies backing its Farapulse and Watchman FLX systems.
Washington Regional’s Walker Heart Institute now offers the Watchman FLX Pro Left Atrial Appendage Closure (LAAC) Device. The ...
With Watchman, Boston Scientific estimates a 20% compound annual growth rate (CAGR) in 2025 with a high market share. Mahoney ...
And what exactly is atrial fibrillation anyway ... like warfarin or aspirin — are not candidates for the WATCHMAN device. Another treatment that just came out this year is called pulsed field ...
persistent atrial fibrillation with the FARAPULSE™ Pulsed Field Ablation System Sub-analysis from OPTION clinical trial highlights consistent safety and efficacy outcomes with the WATCHMAN FLX ...
Boston Scientific (BSX) announced data supporting the use of the FARAPULSE Pulsed Field Ablation System* and the WATCHMAN ...
Looking back, Kokomo resident Mike Beatty knew he had something as a teenager, but he couldn’t put a name to it. Whenever he’d overexert himself, he’d feel “different,” but it would go away with rest.
Similar stroke protection with the WATCHMAN FLX device compared to OAC irrespective ... to improve long-term outcomes for patients with atrial fibrillation," said Dr. Brad Sutton, M.D., chief ...